Cisplatin and carboplatin are active in previously untreated patients with metastatic breast
cancer (MBC) with mean response rates (RRs) of 50 and 32%, respectively. In pretreated …

The role of platinum-based compounds (PBCs) in the treatment of metastatic breast cancer
(MBC) has been extensively studied. As single agents, high response rates have been …

Chemotherapy plays an important role in the management of metastatic breast cancer. The
anthracyclines (doxorubicin, epirubicin) and the taxanes (paclitaxel, docetaxel) are …

Cytotoxic chemotherapy is a mainstay of treatment for advanced breast cancer. Treatment of
metastatic (also called stage IV, advanced, or recurrent) breast cancer is not considered …

Patients with recurrent breast cancer can be divided into three categories: those with
locoregional recurrence, those with distant nonvisceral recurrence, and those with visceral …

Interest in platinum compounds for the treatment of breast cancer has been reawakened
because of preclinical studies indicating synergy of platinum salts with the monoclonal …

Metastatic breast cancer is a partially chemotherapy-sensitive neoplasm. Most
chemotherapy groups have activity in this disease, and the most active single drugs are the …

Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the single-agent activity of carboplatin for metastatic breast cancer. Discuss the …

Cisplatin has had only minimal activity when used as second-and third-line chemotherapy
for metastatic breast cancer (MBC). There have been no phase II studies in the United States …

Anthracyclines and taxanes are the most active agents in the first-line treatment of metastatic
breast cancer. Among the options following clinical resistance to anthracycline and/or …